Source comparison
AOD-9604 vs Tesamorelin: What Each Molecule Actually Is
Tesamorelin is a synthetic analog of human GHRH — specifically the biologically active GHRH(1–44) sequence — modified with a trans-3-hexenoic acid group at the N-terminus to slow its breakdown. It is, in plain terms, a signal to the pituitary gland: it tells t
This comparison does not assign a generated winner or score.
- Tesamorelin is a synthetic analog of human GHRH — specifically the biologically active GHRH(1–44) sequence — modified with a trans-3-hexenoic acid group at the N-terminus to slow its breakdown. It is, in plain terms, a signal to the pituitary gland: it tells the pituitary to synthesize and release the body’s own growth hormone, which in turn raises insulin-like growth factor-1 (IGF-1) and drives a reduction in visceral (deep abdominal) fat.[3] It was the first — and, at approval, the only — treatment indicated for reducing excess abdominal fat in patients with HIV-associated lipodystrophy.[3]
- AOD-9604 is a different kind of molecule entirely. It is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 176–191) with an extra tyrosine added at the N-terminus. It was engineered on the hypothesis that this tail region of GH carries the hormone’s fat-metabolizing (“lipolytic”) activity while leaving behind the parts of GH that raise blood sugar or IGF-1.[5] In other words, the marketing shorthand — “the fat-burning piece of growth hormone” — is a fair description of the design intent. Whether the molecule delivers on that intent in humans is the entire question, and the answer from the clinical record is unflattering.
- The quick-reference table below frames the matchup by attribute. Read the “Human clinical evidence” and “Regulatory status” rows first — they carry most of the weight.
- Molecular class
- C-terminal fragment of human GH (hGH 176–191) plus an N-terminal tyrosine
- Analog of GHRH(1–44), stabilized with a trans-3-hexenoic acid moiety
- Where it acts
- Claimed to act directly on fat cells (lipolysis), without raising GH or IGF-1[5]
- Acts upstream on the pituitary; raises the body’s own GH and IGF-1[3]
- Original research goal
- General obesity / fat loss
- Reduction of excess visceral fat in HIV-associated lipodystrophy
- Human clinical evidence
- Weak / negative: reached Phase 2, a 24-week obesity trial did not beat placebo; the pivotal result was never published[6][8]
- Strong: two multicenter, double-blind, placebo-controlled Phase 3 RCTs (pooled n=806; separate n=404)[1][2]
- Regulatory status
- Not approved anywhere as a weight-loss drug; obesity development ended in 2007[8]
- FDA-approved in 2010 (Egrifta; reformulated as Egrifta SV), HIV-lipodystrophy only[3][4]
- Route studied in humans
- Oral (the injectable “fat-loss” use sold today has no clinical basis)
- Subcutaneous injection, once daily[4]
- Sport status
- Prohibited (WADA)